IPP Bureau
MetroMedi ties up with BMS Fit Club for diabetes management
By IPP Bureau - September 22, 2021
The consultations are virtual and they have launched the Diabetes Reversal Programme to address the issue
Zydus agrees to sell Mifegest and Cytolog to Integrace
By IPP Bureau - September 21, 2021
The purchaser is a part of the portfolio companies of PE firm True North. The said transaction is not a related party transaction.
AYUSH minister Sonowal exhorts researchers to explore Indian traditional medicine
By IPP Bureau - September 21, 2021
Assam is home to more than 1,700 species of medicinal plants
U.S. FDA approves Samsung Bioepis and Biogen’s BYOOVIZ biosimilar
By IPP Bureau - September 21, 2021
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
HUTCHMED initiates a Japan bridging study to Support Surufatinib
By IPP Bureau - September 21, 2021
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Pfizer and BioNTech’s Covid-19 vaccine safe for children aged 5 to 11: study
By IPP Bureau - September 21, 2021
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
Technology to distinguish between bacterial and viral infections cleared
By IPP Bureau - September 21, 2021
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
AAV Production system enables scalable gene therapy workflows
By IPP Bureau - September 21, 2021
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
Glenmark receives ANDA approval for treatment of acne
By IPP Bureau - September 21, 2021
Clindamycin Phosphate Foam, 1% is the generic version of Evoclin Foam, 1%
AstraZeneca to set up API facility in Ireland at an investment of US $ 360 million
By IPP Bureau - September 21, 2021
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
Lincoln Pharma plans to launch Cephalosporin product portfolio soon
By IPP Bureau - September 21, 2021
Cephalosporin is a bactericidal, broad-spectrum, and P-lactam antibiotic originally derived from the fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis among others
RxDx Healthcare receives NABL accreditation
By IPP Bureau - September 20, 2021
RxDx is a chain of primary care driven multispecialty healthcare clinics with two main branches situated in Whitefield and Malleswaram in Bengaluru
Qardio’s remote patient cardiac monitoring service launched
By IPP Bureau - September 20, 2021
It is the first-ever fully remote end-to-end Remote Patient Monitoring (RPM) service to include cardiac arrhythmia analysis in a single, intuitive platform
U.S. FDA concludes inspection of Lupin’s Goa facility with seven observations
By IPP Bureau - September 20, 2021
The company said in a regulatory filing that it was confident of addressing the observations satisfactorily
Imfinzi plus chemotherapy tripled patient survival at 3 years
By IPP Bureau - September 20, 2021
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
